A pharmaceutical firm’s OTC business unit was stagnating in the US and underperforming internationally, so they turned to Marakon. We designed granular resource allocation strategies to unlock profitable growth in US while turning around Mexico and China businesses. These changes drove double digit top line and >2x EBIT in target regions and ultimately resulted in the sale of the business unit at 100% premium to intrinsic value.
The long tail of consumer packaged goods: Are you a stubborn persister or disciplined adapter?
The COVID crisis makes the challenges of CPG companies even harder with price-sensitive consumers trading down, customer demands for higher trade, and consumer...